How American Biotech Companies Are Leading Innovation in Microbiome-Based Drugs
Type-II diabetes remains a significant healthcare concern in the United States, with many patients experiencing difficulty achieving and maintaining recommended blood glucose levels despite ongoing treatment. Rising diabetes prevalence, sedentary lifestyles, unhealthy dietary patterns, an aging population, and challenges related to treatment adherence are increasing the need for effective...
0 Comments 0 Shares 45 Views 0 Reviews
Sponsored